GerardCrinerMD

Pulmonology • Philadelphia, PA

Critical Care Medicine, Pleural Disease

Professor of Medicine, Temple Univ

Join to view full profile

Dr. Criner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Criner's full profile

Already have an account?

Office
3401 N Broad St
Philadelphia, PA 19140
Phone+1 215-707-5864

Fax+1 215-707-6867

Education & Training

Boston University Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1983 - 1986
Temple University HospitalResidency, Internal Medicine, 1979 - 1982
Lewis Katz School of Medicine at Temple UniversityClass of 1979

Certifications & Licensure

PA State Medical License 1980 - 2024
MD State Medical License 1986 - 1988
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Philadelphia Magazine Castle Connolly, 2009-2014
America's Top Doctors Castle Connolly, 2009-2014
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Benefits of Lightweight Ambulatory Oxygen Systems for Individuals With Chronic Obstructive Pulmonary Disease Start of enrollment: 2005 Mar 01
Terminated
Not Applicable
Macrolide Azithromycin to Prevent Rapid Worsening of Symptoms Associated With Chronic Obstructive Pulmonary Disease Start of enrollment: 2006 Mar 01
Completed
Not Applicable
US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study Start of enrollment: 2007 Feb 01
Completed
Phase 2
US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study Start of enrollment: 2007 Aug 01
Completed
Phase 2
Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry Start of enrollment: 2007 Sep 01
Completed
Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study Start of enrollment: 2008 Feb 01
Completed
Phase 2
Long-term Oxygen Treatment Trial Start of enrollment: 2009 Jan 01
Completed
Phase 3
Pennsylvania Study Of Chronic Obstructive Pulmonary Exacerbations Start of enrollment: 2004 Jun 01
Completed
Simvastatin Therapy for Moderate and Severe COPD Start of enrollment: 2010 Mar 01
Terminated
Phase 3
Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD) Start of enrollment: 2012 Apr 01
Completed
Phase 4
Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study Start of enrollment: 2012 Oct 01
Terminated
Not Applicable
Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study) Start of enrollment: 2013 Jul 01
Completed
Not Applicable
Prostaglandin Inhibition for Emphysema Start of enrollment: 2014 Jan 01
Completed
Phase 2
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History Start of enrollment: 2014 Jun 13
Completed
Phase 3
The Frequency of Screening and SBT Technique Trial: The FAST Trial Start of enrollment: 2018 Jan 18
Recruiting
Not Applicable
Respiration Rate Monitoring in COPD Patients Start of enrollment: 2016 Dec 01
Completed
Not Applicable
RejuvenAir® System Trial for COPD With Chronic Bronchitis Start of enrollment: 2020 Jul 09
Active, not recruiting
Not Applicable
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations Start of enrollment: 2019 Aug 26
Active, not recruiting
Phase 3
Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients Start of enrollment: 2020 Jul 01
Completed
Phase 1
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease Start of enrollment: 2022 Jun 28
Recruiting
Not Applicable
Roles: Contact
Tolerance and Acute Effects of a New HFNT Nasal Cannula Start of enrollment: 2022 May 25
Completed
Not Applicable
Roles: Principal Investigator, Contact
Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis Start of enrollment: 2018 Sep 04
Recruiting
Phase 2
Roles: Contact
DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers Start of enrollment: 2020 Aug 24
Active, not recruiting
Roles: Contact
Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD Start of enrollment: 2018 Feb 18
Terminated
Not Applicable
Roles: Contact, Principal Investigator
Functional Lung Imaging in Patients With Respiratory Compromise Undergoing Endobronchial Valve Placement Start of enrollment: 2022 Jul 05
Recruiting
Roles: Principal Investigator, Contact
Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial Start of enrollment: 2020 Dec 17
Active, not recruiting
Phase 3
Roles: Contact
myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home Start of enrollment: 2022 Feb 02
Recruiting
Not Applicable
Roles: Contact
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2) Start of enrollment: 2019 Mar 29
Active, not recruiting
Phase 3
Roles: Contact
Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1) Start of enrollment: 2019 Apr 02
Active, not recruiting
Phase 3
Roles: Contact
Trial of Therapeutic Hypothermia in Patients With ARDS Start of enrollment: 2021 Jun 29
Recruiting
Phase 2
Roles: Sub-Investigator
Clinical Effectiveness Of High Frequency Chest Wall Oscillation (HFCWO) In A Bronchiectasis Population Start of enrollment: 2020 Feb 18
Completed
Roles: Contact
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis Start of enrollment: 2020 Sep 07
Recruiting
Phase 2
Roles: Contact
Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial) Start of enrollment: 2022 Aug 22
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

80 citations
A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM).
Samuel V Kemp, Dirk-Jan Slebos, Alan Kirk, Malgorzata Kornaszewska, Kris Carron
American Journal of Respiratory and Critical Care Medicine. 2017-12-15
11 citations
Meta-analysis and Systematic Review of Bronchoscopic Lung Volume Reduction Through Endobronchial Valves in Severe Emphysema.
Maulin Patel, Junad Chowdhury, Huaqing Zhao, Xiaoning Lu, Stephanie Roth
Journal of Bronchology & Interventional Pulmonology. 2022-07-01
147 citations
Treatment of persistent pulmonary air leaks using endobronchial valves.
John M. Travaline, Robert McKenna, Tiziano De Giacomo, Federico Venuta, Steven R. Hazelrigg
Chest. 2009-08-01

Journal Articles

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Gerard J Criner, Lavannya Pandit, The New England Journal of Medicine
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19
Robert L Gottlieb, Gerard J Criner, Onyema Ogbuagu, Kathleen M Mullane, Anuj Gaggar, Diana M Brainard, Gregory Huhn, JAMA
Association of Dysanapsis with Chronic Obstructive Pulmonary Disease Among Older Adults
Alain Bertoni, Gerard Criner, Mark T Dransfield, Meilan K Han, Nadia N Hansel, Erin D Michos, Elizabeth C Oelsner, Karol E Watson, JAMA
A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT
Anil Vachani, William N Rom, Gerard Criner, Harvey Pass, Clinical Cancer Research
Join now to see all

Authored Content

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19August 2020
Failure of Low-Dose Theophylline to Prevent Exacerbations in Patients with COPDOctober 2018
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary DiseaseSeptember 2017
Join now to see all

Press Mentions

Endobronchial Valves: Sustained Improvement in EmphysemaMay 25th, 2023
Help COPD Patients with More Probing CareSeptember 12th, 2022
PRE-PROOF Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation PRE-PROOFJune 29th, 2022
Join now to see all

Committees

Member, Expert Panel, American College of Chest Physicians 2015 - Present